Page 6 - Cell Therapy Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Therapy Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Therapy Development Today - Breaking & Trending Today

Rising at 17.50% CAGR, Gene Synthesis Market Size to Reach

Published: August 16, 2022

[215+ Pages Report] The size & share of the Global Gene Synthesis Market is predicted to grow to around 4,021.41 USD Million by 2028 with a compound annual...

Source: globenewswire.com

$European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy - Vimarsana News$

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy

Published: June 20, 2022

Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated its type II variation application for extension of the indication for Breyanzi (lisocabtagene maraleucel) to treat adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) ...

Source: pharmiweb.com

Global Gene Synthesis Market By Method, By Service Type, By

Published: March 1, 2022

The Global Gene Synthesis Market size is expected to reach $5. 2 billion by 2027, rising at a market growth of 17. ...

Source: globenewswire.com

$Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results - Vimarsana News$

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results

Published: December 11, 2021

Phase 3 TRANSFORM study shows Breyanzi significantly improved event-free survival (EFS) vs. chemotherapy plus autologous stem cell transplant, with a 65% reduction in risk of EFS events in first disclosure of results presented at ASH 2021Breyanzi showed a manageable safety profile and no new safety signals observed,...

Source: pharmiweb.com